Stay updated on ARO-APOC3 in FCS Clinical Trial

Sign up to get notified when there's something new on the ARO-APOC3 in FCS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ARO-APOC3 in FCS Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page now displays the PALISADE study record for plozasiran, including its eligibility criteria, study design, outcomes, locations, and documents, instead of a 403 error.
    Difference
    84%
    Check dated 2026-11-07T13:53:10.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page remains a 403 Forbidden error page; its footer revision changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-10-31T14:42:39.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    A banner announces an NIH terminology transition and links to updates and FAQs. The study record area continues to display a 403 error.
    Difference
    1%
    Check dated 2026-10-24T16:06:18.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The footer now identifies the ClinicalTrials.gov site as revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-17T15:51:16.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T15:48:05.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    The study record page displays a 403 Forbidden message instead of its study content, with a Home link.
    Difference
    0.5%
    Check dated 2026-10-03T15:57:47.000Z thumbnail image

Stay in the know with updates to ARO-APOC3 in FCS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ARO-APOC3 in FCS Clinical Trial page.